Together We Discover

Reaching Patients Through
Immunology Innovation

Half Year 2022 Financial Results and Second Quarter Business Update

JULY 28, 2022

argenx

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Safe Harbor: Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding the VYVGART launch strategy to make VYVGART available in Europe, China, Canada and select other regions, the expected European Commission (EC) approval in the third quarter of 2022, Zai Lab and Medison's respective pending approvals in China and Israel; its plan to expand its leadership position in FcRn blockade to include ten autoimmune indications by the end of 2022; its expectations about its pipeline progress; its collaboration with the University of Colorado Anschutz Medical Campus and UCHealth to create OncoVerity, Inc.; the therapeutic potential of its product candidates; the intended results of its strategy and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; and the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Strong Execution in First Half 2022

1	Global VYVGART® Sales	$75M in net Q2 product sales
2	Global Launch	Strong launch performance in U.S. and Japan EU approval expected in Q3; BLA accepted in China
3	Positive Phase 3 Data	Positive ADVANCE-IV data in ITP Positive ADAPT-SC data in gMG - BLA submission by YE
4	Broad Efgartigimod Pipeline	ADHERE (CIDP) data expected 1Q23 ADVANCE-SC (ITP) and ADDRESS (PV) data expected 2H23
5	Well-Financed	$2.6B in cash at end of Q2

VYVGART Launch Shows Continued Momentum

Addressing the unmet need in gMG

Backed by solid science and data

$75M

2Q Net Product Revenues

Significant physician and patient demand

Broad coverage achieved in two quarters

argenx

ADAPT-SC Bridging Study

Innovative Trial Accelerated Path Forward

adapt sc
myasthenia gravis study

Leveraged PK/PD from ADAPT

Leveraged correlation between pharmacodynamic and clinical effect as observed in ADAPT

Met Primary Endpoint

Met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to IV administration

Secondary endpoints show clinical improvement consistent with IV administration

2023 Launch

BLA to be submitted by end of 2022

ADVANCE-IV Phase 3

Results Support Path Forward

Primary Endpoint Met

Statistically significant and clinically meaningful improvement in platelet counts over placebo

Meaningful Patient Benefit Observed

Fast and robust platelet count improvement over placebo

Ability for every other week dosing confirmed

Favorable Safety & Tolerability Observed

Chronic administration of VYVGART was well-tolerated

Safety profile consistent with previous clinical trials

Multiple Data Readouts in 2023

First Quarter 2023

Second Half 2023

Advancing Cusatuzumab in AML with OncoVerity

Leveraging expertise of our partners

Co-creation to maximize value creation potential

4th spinoff to emerge from discovery engine

Combining novel translational biology insights on the role of CD70/CD27 pathway in AML…

…With encouraging data from our first-in-class asset

argenx

Second Quarter 2022 Financial Results

(in millions of $)	Three months ended June 30		Six months ended June 30	
	2022	2021	2022	2021
Product net sales	74.8		96.0	
US	*73.2*		*94.3*	
Japan	*1.5*		*1.5*	
Other	*0.1*		*0.1*	
Collaboration revenue and other	10.4	320.1	20.7	498.6
Total operating income	**85.2**	**320.1**	**116.7**	**498.6**
Cost of sales	(5.0)		(6.4)	
R&D expenses	(126.9)	(151.6)	(278.9)	(273.9)
SG&A expenses	(127.8)	(73.3)	(228.7)	(129.6)
Total operating expenses	**(259.7)**	**(224.9)**	**(513.9)**	**(403.5)**
Other income / (expenses)	(34.2)	8.5	(38.7)	(32.0)
Profit / (loss) for the period	**(208.8)**	**103.6**	**(435.9)**	**63.2**

Ended second quarter with **$2.6B cash**

Other income / (expenses) includes financial income / (expenses), exchange gains / (losses) and tax
Cash reflects cash, cash equivalents and current financial assets.

Executing on VYVGART Launch Priorities

Meeting our stakeholders where they are

- Empower Patients to Demand Better
- Best-in-Class Patient Support
- Rapid HCP Adoption of VYVGART
- Enable Appropriate Access

$75M
2Q 2022 Net Product Sales



argenx

Significant Growth in Patients on Therapy

APPROXIMATELY

1400

PATIENTS ON VYVGART GLOBALLY

"I no longer have to use two hands to brush my teeth - one to hold the toothbrush and the other to hold my arm up. I was able to keep my eyes open enough to read a book for the first time in 5 years. I'm excited to return to my classroom this fall with more energy and strength!"

– VYVGART® Patient*

* Patient quoted is an adult returning to the classroom as a teacher

Shifting Prescribers from Initial Use to Broad Adoption

78% of physicians have written **1 or 2 scripts;** Shift to broad adoption key indicator of growth trajectory

Key Pillars of VYVGART Value-Based Agreement

Most VYVGART-specific policies are favorable and aligned to label, with prior authorization median of 6 months

J-Code in effect July 1, 2022

4Q 2021

25% Of Covered Lives

1Q 2022

62% Of Covered Lives

2Q 2022

85% Of Covered Lives

Broad coverage achieved

Global gMG Launch Progressing

United States

VYVGART Approved December 17, 2021

Global

Japan
Launched May 9, 2022

Europe
Positive CHMP opinion
Anticipated EC decision in Q3 2022

China (Zai Lab)
Filed and accepted in 2Q 2022

Canada

Gulf Region (GenPharm)

Israel (Medison)
Filed in 2Q 2022

Central and Eastern Europe (Medison)

Expand Global Reach to People Living with gMG

Eri, living with gMG

LEADING WITH THE SCIENCE, FOCUSED ON THE PATIENT

Progressing Toward ‘argenx 2025’

Reach patients globally

- Drive continued momentum in U.S. and Japan
- Prepare for EU launch with initial efforts in Germany

Expand gMG offering

- Bring additional optionality to gMG community with SC launch in 2023

Advance pipeline

- Phase 3 data readouts of efgartigimod in 3 indications in 2023
- Expand next pipeline-in-a-product opportunity with ARGX-117
- Continue development of early stage assets, including ARGX-119